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Atrial fibrillation (AF) is frequently encountered in acute
ST-elevation myocardial infarction (STEMI) as well as in
elderly patients, and is the most common cardiac arrhythmia
in general. Its incidence increases with age and above 80 years
it affects approximately 8 % of patients [1]. However, the
clinical and prognostic significance depends on the setting in
which it occurs. Themost likely pathophysiological reasons to
develop AF in STEMI are acute ischaemia of the atria and
conduction system resulting in electrophysiological changes
and vulnerability, and haemodynamic deterioration as a result
of more advanced coronary artery disease in elderly patients.
Other accompanying phenomena such as acute ischaemic
mitral regurgitation, left ventricular hypertrophy and left atrial
distension together with fibrosis are also likely to play a role.
These factors, mostly in combination, create an ideal substrate
for atrial fibrillation, but are also major determinants of a
worse prognosis. Whether atrial fibrillation itself contributes
to deterioration of the clinical status and thus may be the cause
and not only the sign of a grim prognosis remains unclear.
As Martínez-Sellés and co-workers nicely demonstrate in
their small series of very old (≥89 years) patients with STEMI
in the current issue of the Netherlands Heart Journal, it simply
means bad news, especially if the patient was in sinus rhythm
before (new-onset AF) [2]. This is in accordance with the
findings of another study, where age was an independent
variable (together with haemodynamic state) for the occur-
rence of new-onset AF after primary angioplasty, and was
associated with increased mortality [3]. The same finding
was reported from other STEMI cohorts and patients treated
with different reperfusion modalities [4, 5]. Interestingly
enough, already in 1961 Thomas James noticed that in the
pre-reperfusion era, the overall incidence of AF in STEMI was
approximately 10 %, and if it occurred mortality was
extremely high [6]. In the current study, about 70 % of the
patients did not receive reperfusion therapy and only 20 %
underwent primary angioplasty, which means that the studied
nonagenarians are at extreme risk of dying after their STEMI if
they develop AF. Part of the bad news is the fact that the
majority did not have reperfusion therapy at all, but whether
timely reperfusion would have led to better survival is highly
speculative. In the Zwolle database of all patients undergoing
primary angioplasty for STEMI between 1998 and 2008, out
of almost 8,000 patients, 1.6 % were between 85 and 90 years
of age, and only 0.6 % were nonagenarian (unpublished data)
but these numbers have been increasing rapidly over the last
few years [4]. Survival shows a sharp decline in these very old
patients, irrespective of additional treatment or the occurrence
of atrial fibrillation [7].
It is remarkable that in the current study, new-onset AF did
not influence in-hospital mortality, and only during longer
follow-up was the extreme mortality observed in the new-
onset AF patients, which makes us wonder and speculate
about the possible pathophysiological mechanism. One pos-
sible cause of death might be related to the high risk of stroke,
but by presenting us the CHA2DS2 VASc scores the authors
suggest that this may not explain the difference, which is an
important finding. This may also have implications for thera-
py at discharge and follow-up, because the general evidence-
based medication has to be scrutinised against possible alter-
natives, considering increased bleeding risk and complex
pharmacological interactions in very old persons. Older pa-
tients with STEMI do in general have a different profile than
the younger group and usually have longer ischaemic time
delays, are more likely to be women and diabetics, often have
a history of previous revascularisation and MI, and a higher
incidence of left ventricular failure on admission. This makes
them high-risk patients anyway, but atrial fibrillation and very
old age seem to be ruthless harbingers of death. However, the
elderly are in general subjected tomore conservative treatment
strategies. As elderly STEMI patients are less likely to receive
evidence-based treatment, including reperfusion therapy, there
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may be a hidden message in this observation for everyone in
charge of treating patients with STEMI: consider primary
angioplasty in every old patient with new-onset AF, as this
is the best treatment option available [8, 9]. This is even more
important as the population ages and the number of elderly
patients presenting with acute myocardial infarction will con-
tinue to increase. The decision to treat or not treat an elderly
individual with primary angioplasty needs good clinical dis-
cernment, but on the other hand gives little time for judgment
or deliberation because of the critical ischaemic time delays.
Will timely reperfusion improve prognosis in these very old
patients? We do not know the answer but the door to the cath-
lab should also be wide open, even for very old STEMI
patients with comorbidities and age-related problems, regard-
less of whether they present with new-onset AF. This unique
patient group will never be suitable for randomised clinical
trials for obvious reasons and we have to rely on observational
data as derived from this small study.
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